Fusion Pharmaceuticals has tons of upside, says Raymond James
Raymond James analyst Rahul Sarugaser maintained an “Outperform” rating on Fusion Pharmaceuticals in a Tuesday client report, saying the company is breaking new ground in cancer research.
John Valliant Raymond James Rahul Sarugaser Society For Nuclear Medicine Fusion Pharmaceuticals Fusion Pharmaceuticals Stock
Source: cantechletter.com